Lineage Cell Therapeutics Inc
LCTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$331.57M
Close$
$-1.33
211% downside
Current Fair Value
211% downsideOvervalued by 211% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $331.57 Million |
|---|---|
| Enterprise Value | $299.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 1.6 |
| Outstanding Shares | 245,029,000 |
Return
| Return on Equity | -119.18% |
|---|---|
| Return on Assets | -58.62% |
| Return on Invested Capital | -22.55% |
Valuation & Multiples
| P/E Ratio | -5.08 |
|---|---|
| PEG | -31.22 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 20.28 |
| Enterprise Value to EBIT | -13.11 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$3.60 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$4.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1894▼ 86.88% |
|---|---|
| Total Calls | 115,100▲ 80.97% |
| Total Puts | 21,800▼ 67.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 48.54%▲ 4.12% |
|---|---|
| Total Invested | $176.47M▲ 3.95% |
| Investors Holding | 132▲ 7.00% |
ESG Score
No data
About Lineage Cell Therapeutics Inc
CEO: Brian Culley